SCHEMBL2333481

SCHEMBL2333481

O=Cc1cc(-c2ccccc2)c(Cl)s1

nearest known ligand 0.43

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CYP2A6 P11509 6/20 0.43
MEN1 O00255 5/20 0.35
KMT2A Q03164 5/20 0.35
PSMD14 O00487 1/20 0.35
LMNA P02545 1/20 0.35
MAPT P10636 1/20 0.35
BACE1 P56817 1/20 0.34
ALDH1A1 P00352 1/20 0.34
HPGD P15428 1/20 0.34
SMN1; SMN2 Q16637 1/20 0.34
L3MBTL1 Q9Y468 1/20 0.34
CTRC Q99895 2/20 0.34
RAB9A P51151 2/20 0.34
CYP2E1 P05181 1/20 0.34
CYP3A4 P08684 1/20 0.34
CYP2C9 P11712 1/20 0.34
CYP2B6 P20813 1/20 0.34
CYP2C19 P33261 1/20 0.34
APP P05067 1/20 0.34
NR1H2 P55055 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1823851 0.79 CYP2A6 (0.44) CYP2A6MEN1KMT2AMAPTBACE1
SCHEMBL2836255 0.79 CYP2A6 (0.48) CYP2A6MEN1KMT2ALMNABACE1
SCHEMBL1826512 0.78 CYP2A6 (0.43) CYP2A6MAPTBACE1HPGDSMN1; SMN2
SCHEMBL8300939 0.78 CYP2A6 (0.43) CYP2A6MEN1KMT2ALMNAMAPT
SCHEMBL5924594 0.77 CYP2A6 (0.35) CYP2A6MAPTBACE1ALDH1A1SMN1; SMN2
SCHEMBL197250 0.74 CYP2A6 (0.61) CYP2A6MEN1KMT2ALMNAMAPT
SCHEMBL31178606 0.74 CYP2A6 (0.40) CYP2A6MEN1KMT2ALMNAMAPT
SCHEMBL10088620 0.74 CYP2A6 (0.40) CYP2A6MAPTALDH1A1L3MBTL1APP
SCHEMBL2836245 0.73 GSTP1 (0.42) CYP2A6MEN1KMT2ALMNAMAPT
SCHEMBL11525332 0.72 HSD17B1 (0.49) CYP2A6MEN1KMT2ALMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20110224208-A1 NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION KATHOLIEKE UNIVERSITEIT LEUVEN, K.U. LEUVEN R&D (BE) 2011-09-15 US disclosed
EP-2358682-A2 ISOQUINOLONE DERIVATIVES AS INHIBITORS OF PLAVIVIRUS REPLICATION Katholieke Universiteit Leuven, K.U. Leuven R&D (BE) 2011-08-24 EP disclosed
WO-2010055164-A2 NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION KATHOLIEKE UNIVERSITEIT LEUVEN, K.U.LEUVEN R&D (BE) 2010-05-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110224208-A1 NOVEL INHIBITORS OF FLAVIVIRUS REPLICATION MAVS, IRF3, EIF2AK2 CYP2A6 1045/4885MEN1 4759/4885KMT2A 3433/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.